导读
“随着京津冀协同发展战略加速推进，京津冀地区已成为生物医药产业重要聚集地之一，产业链和创新链‘双链’融合取得积极进展。要进一步深化三地生物医药协同合作，开展跨区域联合培育集群，充分发挥科技创新和产业发展资源富集优势，推进产业由集聚发展向集群发展的全面提升。”工业和信息化部消费品工业司司长何亚琼在“京津冀生命健康产业集群协同发展论坛暨大兴推介会”上表示。
一、京津冀健康产业取得积极进展
目前，我国已成为世界医药大国，建立了系统、完整的产业链，可生产医药产品品种、规模化生产能力位居全球前列。生命健康产业是京津冀协同发展程度最高、成效最丰富的领域之一。
何亚琼指出，“十四五”以来，我国医药工业全行业研发投入年均增长23%，共有82个国产创新药获批上市，4个创新药在发达国家完成上市注册，217个创新医疗器械获批上市，创新产品新增销售占全行业营业收入增量近30%，产业创新能力显著提高。我国医药工业正在以前所未有的速度发展，特别是跟信息技术的紧密结合、跟人工智能的结合，带来了全新的思考和发展空间。 数字化转型网（www.szhzxw.cn）
据了解，京津冀生物医药产业集群已经初步形成。北京市经济和信息化局党组书记、局长姜广智表示，伴随京津冀协同发展战略深入推进，三地生命健康产业分工合作的基本架构成形，产业取得长足发展。2022年，京津冀医药工业总产值超过4000亿元，占全国比重超过20%，21家企业上榜“2021年中国医药工业百强榜”，共获批国家一类新药17个，创新型医疗器械60个，专精特新“小巨人”企业82家，国家级技术创新平台33家，区域内创新策源、技术转化和先进制造的协同生态更加健全，新业态、新产业、新服务持续涌现。2022年底，京津冀生命健康产业集群入选国家首批先进制造业集群，凸显了对京津冀协同发展的示范引领作用。
何亚琼表示，京津冀生命健康集群是工信部重点培育的国家先进制造业集群之一，在技术、人才、成本方面有非常好的竞争潜力。北京·沧州渤海新区生物医药园、石家庄高端生物产业基地等合作园区建设有效推动了三地生物医药产业合作。
“2022年，京津冀生命健康集群集聚企业超过5000家，国家高新技术企业1300余家，为我国生命健康产业发展贡献强大力量。”何亚琼表示。 数字化转型网（www.szhzxw.cn）
二、打造生命健康产业创新和先进制造高地
先进制造业集群是产业分工深化和集聚发展的高级形式，培育发展先进制造业集群，是推进新型工业化的重要内容，有利于形成协同创新、人才集聚、降本增效等规模效应和竞争优势。
“一年来，我们三地加强沟通、密切协作，联合编制集群培育提升三年行动方案，进一步明确行动路径。下一步，我们将在工信部的指导下，围绕推进新型工业化这一关键任务，重点从以下三方面着力，全力推动京津冀生命健康集群高质量发展。”姜广智表示。
1. 深化产业链协同建设。
立足京津冀创新资源丰富和制造能力雄厚的优势，以推动三地协同创新和产业协作为主线，以共同建设产业廊道和医药服务等多个特色增长引擎为依托，着力推动区域内原料药等传统产业升级延链，创新药械等新兴产业补链强链，数字医疗等未来产业加快建链，合力做大产业规模、做强产业链韧性。
2. 优化产业发展生态。
全力推动创新资源向企业集聚，激活科研和临床资源创新活力，促进科技转化和产业化成果落地；加快破除市场壁垒，推动优化创新药械上市回报机制；强化医药服务集群建设，建设公共服务平台、医药创业孵化器等，发展研发生产服务一体化模式；加强智慧药品供应链服务体系、生物制剂冷链仓储配送体系、中药质量服务追溯体系等建设和应用，健全多元化服务配套。 数字化转型网（www.szhzxw.cn）
3. 完善集群治理结构。
增进产学研各方协同共治，打造政府营造政策环境、企业发挥主体作用、社会力量广泛参与的工作格局。支持大型企业以链主需求牵引、产业投资孵化等方式，开放生产能力、供应链等资源，构建大中小企业共享发展生态。开展“织网工程”，支持组建产业发展联盟，搭建企业供需对接平台和交流活动。强化重点园区市场化运行能力，完善内部生态，探索多元协同管理新模式。
“北京市经济和信息化局将继续与两地工信部门共同努力，与行业各界一道合作，全力推进集群建设，打造对标国际、领先全国的生命健康产业创新和先进制造高地。”姜广智表示。
三、提升区域产业一体化发展水平
“当前，世界百年未有之大变局加速演变和我国社会主义现代化建设新征程开局起步相互交融，‘十四五’时期，我国医药工业发展仍处于重要战略机遇期。”何亚琼表示，京津冀三地作为全国医药健康产业重要承载地，要不断激活企业和研发机构创新动力，加速推进新一代抗体、细胞与基因治疗、数字医疗等创新要素聚集，提升高端医疗设备的生产制造水平，扩大高端产品和优质产品供给，推动产业数字化转型，促进全产业链绿色低碳发展。 数字化转型网（www.szhzxw.cn）
何亚琼表示，要着力提升京津冀产业链稳定性和竞争力。针对产业链关键环节和重要产品持续发力，支持重点企业在新型疫苗、基因治疗、免疫细胞治疗等方面开展攻关，攻克一批产业链共性技术和关键核心技术。推动开放型创新载体建设，加强重点实验室等平台建设，打造产学研结合的跨京津冀生物医药产业创新生态，联合实施一批科技重大项目。以京津冀龙头企业为支撑，重点布局建设企业技术中心、培育制造业创新中心、打造技术创新示范企业，提升产业集中度和竞争力。
“我们要加快产品创新和产业化技术突破。立足本土资源和优势，面向全球市场，紧盯新靶点、新机制药物开展研发布局，积极引领创新。要加快生物医药场景和案例的创设，加强典型经验总结和优秀案例推广，提升数字科技在生物医药领域的应用能力。”何亚琼表示。
何亚琼表示，未来，要结合地方实际和资源禀赋，深化区域合作，优化中长期发展规划，提升系统政策支持力度，科学布局、错位发展、协同联动，全面提升区域产业一体化发展水平，推动京津冀生物医药产业再上新台阶。 数字化转型网（www.szhzxw.cn）
翻译：
The Beijing-Tianjin-Hebei bio-pharmaceutical industrial cluster has taken shape
Introduction
“With the acceleration of the Beijing-Tianjin-Hebei coordinated development strategy, the Beijing-Tianjin-Hebei region has become one of the important gathering places of the biomedical industry, and the” double chain “integration of the industrial chain and innovation chain has made positive progress. It is necessary to further deepen the collaborative cooperation in biomedicine among the three places, carry out cross-regional joint cultivation of clusters, give full play to the advantages of scientific and technological innovation and industrial development resource enrichment, and promote the comprehensive upgrading of industrial development from cluster development to cluster development.” He Yaqiong, director of the Department of Consumer Goods Industry of the Ministry of Industry and Information Technology, said at the “Beijing-Tianjin-Hebei Life and Health Industry Cluster Coordinated Development Forum and Daxing Promotion Meeting.”
The Beijing-Tianjin-Hebei health industry has made positive progress
At present, China has become a major pharmaceutical country in the world, established a systematic and complete industrial chain, and can produce pharmaceutical product varieties and large-scale production capacity in the forefront of the world. Life and health industry is one of the areas with the highest degree of coordinated development and the most fruitful results in the Beijing-Tianjin-Hebei region.
Source: Photo network
He Yaqiong pointed out that since the “14th Five-Year Plan”, China’s pharmaceutical industry industry-wide R&D investment has grown by 23% on average annually, a total of 82 domestic innovative drugs have been approved for listing, 4 innovative drugs have completed listing registration in developed countries, 217 innovative medical devices have been approved for listing, new sales of innovative products account for nearly 30% of the industry’s revenue increment, and industrial innovation capacity has been significantly improved. China’s pharmaceutical industry is developing at an unprecedented speed, especially the close combination of information technology and artificial intelligence, which has brought new thinking and development space. 数字化转型网（www.szhzxw.cn）
It is understood that the Beijing-Tianjin-Hebei bio-pharmaceutical industry cluster has initially taken shape. Jiang Guangzhi, secretary of the Party Group and director of the Beijing Municipal Bureau of Economy and Information Technology, said that with the in-depth promotion of the coordinated development strategy of Beijing, Tianjin and Hebei, the basic structure of the division of labor and cooperation in the life and health industry of the three places has taken shape, and the industry has achieved considerable development. In 2022, the total output value of the Beijing-Tianjin-Hebei pharmaceutical industry exceeds 400 billion yuan, accounting for more than 20% of the national proportion. 21 enterprises are listed on the “Top 100 China Pharmaceutical Industry in 2021”, with 17 national first-class new drugs approved, 60 innovative medical devices, 82 specialized and special “little giant” enterprises, and 33 national-level technological innovation platforms. The collaborative ecology of innovation sources, technology transformation and advanced manufacturing in the region is more sound, and new business forms, new industries and new services continue to emerge. By the end of 2022, the Beijing-Tianjin-Hebei life and health industry cluster was selected as the first advanced manufacturing cluster in the country, highlighting the demonstration and leading role of the coordinated development of Beijing-Tianjin-Hebei.
He Yaqiong said that the Beijing-Tianjin-Hebei life and Health cluster is one of the national advanced manufacturing clusters focused on by the Ministry of Industry and Information Technology, and has very good competitive potential in terms of technology, talent and cost. The construction of cooperation parks such as Beijing · Cangzhou Bohai New Area Bio-Pharmaceutical Park and Shijiazhuang high-end Bio-industrial Base has effectively promoted the bio-pharmaceutical industry cooperation among the three places. 数字化转型网（www.szhzxw.cn）
“In 2022, the Beijing-Tianjin-Hebei Life and Health Cluster will gather more than 5,000 enterprises and more than 1,300 national high-tech enterprises, making a strong contribution to the development of China’s life and health industry.” He Yaqiong said.
To create a life and health industry innovation and advanced manufacturing highland
Advanced manufacturing clusters are advanced forms of industrial division of labor deepening and agglomeration development. Cultivating and developing advanced manufacturing clusters is an important part of promoting new industrialization, and is conducive to forming scale effects and competitive advantages such as collaborative innovation, talent agglomeration, cost reduction and efficiency increase. 数字化转型网（www.szhzxw.cn）
“Over the past year, we have strengthened communication and close cooperation among the three places, jointly prepared a three-year action plan for cluster cultivation and upgrading, and further clarified the path of action.” In the next step, under the guidance of the Ministry of Industry and Information Technology, focusing on the key task of promoting new industrialization, we will focus on the following three aspects to promote the high-quality development of the Beijing-Tianjin-Hebei life and health cluster.” Kang Guangzhi said.
1. Deepen industrial chain coordination.
Based on the advantages of the rich innovation resources and strong manufacturing capacity of the Beijing-Tianjin-Hebei region, to promote collaborative innovation and industrial collaboration among the three places as the main line, and to jointly build industrial corridors and medical services and other characteristic growth engines, we will strive to promote the upgrading and extension of traditional industries such as apis in the region, the reinforcement and strengthening of new industries such as innovative pharmaceutical equipment, and accelerate the construction of future industries such as digital medical. We will work together to expand the scale of industries and strengthen the resilience of industrial chains. 数字化转型网（www.szhzxw.cn）
2. Optimize the industrial development ecology.
Make every effort to promote the concentration of innovation resources to enterprises, activate the innovation vitality of scientific research and clinical resources, and promote the transformation of science and technology and the landing of industrialization achievements; Accelerate the breaking down of market barriers, promote the optimization of innovative pharmaceutical device listing return mechanism; Strengthen the construction of medical service clusters, build public service platforms, medical business incubators, etc., and develop the integrated mode of R&D, production and service; We will strengthen the construction and application of smart drug supply chain service systems, biologics cold chain storage and distribution systems, and traditional Chinese medicine quality service traceability systems, and improve diversified service supporting facilities. 数字化转型网（www.szhzxw.cn）
3. Improve the cluster governance structure.
We will enhance the coordination and co-governance of industry, universities and research institutes, and create a work pattern in which the government creates a policy environment, enterprises play a major role, and social forces are widely involved. We will support large enterprises in opening up production capacity, supply chain and other resources by means of leading demand and industrial investment incubation, and build a shared development ecosystem for large, small and medium-sized enterprises. Carry out the “weaving project”, support the formation of industrial development alliances, and build enterprise supply and demand docking platforms and exchange activities. We will strengthen the market-oriented operation capacity of key parks, improve the internal ecology, and explore new models of diversified and coordinated management.
“The Beijing Municipal Bureau of Economy and Information Technology will continue to work together with the industry and information technology departments of the two places, and cooperate with all sectors of the industry to promote the construction of the cluster, and create an international standard, leading the country’s life health industry innovation and advanced manufacturing highland.” Kang Guangzhi said. 数字化转型网（www.szhzxw.cn）
Enhance the level of regional industrial integration
“At present, the accelerated evolution of the world’s largest changes in a century and the start of the new journey of China’s socialist modernization drive blend with each other, the ’14th Five-Year Plan’ period, the development of China’s pharmaceutical industry is still in an important period of strategic opportunities.” He Yaqieng said that the three places in Beijing, Tianjin and Hebei, as an important carrier of the national pharmaceutical and health industry, should continuously activate the innovation power of enterprises and research and development institutions, accelerate the accumulation of innovative factors such as new generation of antibodies, cell and gene therapy, and digital medical treatment, improve the production and manufacturing level of high-end medical equipment, expand the supply of high-end products and high-quality products, and promote the digital transformation of the industry. We will promote green and low-carbon development of the entire industrial chain.
He Yaqiong said that efforts should be made to enhance the stability and competitiveness of the Beijing-Tianjin-Hebei industrial chain. Continue to focus on key links and important products in the industrial chain, support key enterprises to carry out research in new vaccines, gene therapy, immune cell therapy and other aspects, and conquer a number of common technologies and key core technologies in the industrial chain. We will promote the construction of open innovation carriers, strengthen the construction of platforms such as key laboratories, create a cross-Beijing-Tianjin-Hebei biomedical industry innovation ecology that integrates industry, university and research, and jointly implement a number of major scientific and technological projects. With the support of leading enterprises in the Beijing-Tianjin-Hebei region, we will focus on the construction of enterprise technology centers, the cultivation of manufacturing innovation centers, and the creation of technological innovation demonstration enterprises to enhance industrial concentration and competitiveness.
“We should speed up product innovation and industrial technological breakthroughs. Based on local resources and advantages, facing the global market, focusing on new targets and new mechanism drugs to carry out research and development layout, and actively lead innovation. It is necessary to accelerate the creation of biomedical scenarios and cases, strengthen the summary of typical experiences and the promotion of excellent cases, and enhance the application ability of digital technology in the field of biomedicine.” He Yaqiong said.
He Yaqiong said that in the future, it is necessary to deepen regional cooperation in combination with local realities and resource endowments, optimize medium – and long-term development plans, enhance systematic policy support, scientific layout, dislocation development, and synergy, comprehensively improve the level of regional industrial integration, and promote the Beijing-Tianjin-Hebei biomedical industry to a new level. 数字化转型网（www.szhzxw.cn）
本文由数字化转型网（www.szhzxw.cn）转载而成，来源于中国工业报；编辑/翻译：数字化转型网宁檬树。
免责声明: 本网站(https://www.szhzxw.cn/)内容主要来自原创、合作媒体供稿和第三方投稿，凡在本网站出现的信息，均仅供参考。本网站将尽力确保所提供信息的准确性及可靠性，但不保证有关资料的准确性及可靠性，读者在使用前请进一步核实，并对任何自主决定的行为负责。本网站对有关资料所引致的错误、不确或遗漏，概不负任何法律责任。
本网站刊载的所有内容(包括但不仅限文字、图片、LOGO、音频、视频、软件、程序等) 版权归原作者所有。任何单位或个人认为本网站中的内容可能涉嫌侵犯其知识产权或存在不实内容时，请及时通知本站，予以删除。
